Proposal for a Germline Expert Panel to Improve Variant Reclassification in Japan

IF 4.3 2区医学 Q1 ONCOLOGY

Cancer Science Pub Date : 2025-07-24 DOI:10.1111/cas.70158

Kazuki Yamazawa

引用次数: 0

Abstract

This letter argues that Japan's dependence on a single foreign company for classifying germline variants is delaying critical treatment for cancer patients. The author proposes establishing a national “Germline Expert Panel” to provide independent, timely oversight, and ensure patients receive appropriate care.

Abstract Image

查看原文本刊更多论文

在日本建立生殖系专家小组以改进变异再分类的建议。

这封信认为，日本依赖一家外国公司对生殖细胞变异进行分类，这拖延了对癌症患者的关键治疗。作者建议建立一个全国性的“生殖系专家小组”，以提供独立、及时的监督，并确保患者得到适当的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Science 医学-肿瘤学

自引率

3.50%

发文量

406

审稿时长

2 months

期刊介绍： Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.